Insmed Incorporated develops therapies for serious and rare diseases globally. They offer ARIKAYCE for M. avium complex lung disease as part of a combination antibacterial regimen. Brensocatib is being developed to treat bronchiectasis and other neutrophil-mediated diseases. Treprostinil Palmitil Inhalation Powder treats pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |